Abstract
Colorectal cancer (CRC) is usually treated with oxaliplatin-based regimens in stages II, III and IV as standard of care. However, no predictive oxaliplatin biomarker has ever been fully validated despite intensive research. Here we aimed to discover a biomarker of early progression on oxaliplatin based chemotherapy with potential use in the clinic to guide therapy selection.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
